Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Debt Investor Presentation (June 2021)
40 slides from Fresenius SE & Co. KGaA's debt investor presentation, June 2021
Slide 1: Credit Presentation June 2021
Credit Presentation June 2021
Slide 2: Safe harbor statement
Safe harbor statement No reliance may be placed for any purpose whatsoever on the information or opinions contained in the presentation or on its completeness, accuracy of fairness. No representation or warranty, express or implied, is made or given by or on behalf of Fresenius or any of its respect
Slide 3: Agenda
Agenda 02 03 04 01 Strategic update Financial review Credit highlights Q1/21 & Company Outlook FY/21 overview Credit Presentation June 2021 © Fresenius SE & Co. KGaA 3
Slide 4: A global leader in health care products and services
A global leader in health care products and services in sales Long-term (FY/2020) opportunities in growing, € 36.3 bn non-cyclical markets Global presence Strong financial in 100+ performance countries and cash flow 100 + generation Leading Employees market worldwide positions (as of Mar 31, 2021) #
Slide 5: Investment highlights
Investment highlights Diversified healthcare Group Leading positions in Resilient business model with four strong business growing non-cyclical based on megatrends segments markets healthcare and demographics Purpose-driven business Strong financial Commitment to delivers sustainable performance and
Slide 6: Global trends offer growth opportunities for Fresenius
Global trends offer growth opportunities for Fresenius 4x Increasing national income Generic GDP per capita quadrupled Growing drugs over last 20 years in emerging save the US markets and developing healthcare sector Growth in emerging healthcare 293bn +6.3% economies system4 markets over the next p
Slide 7: Environment, Social and Governance: Setting the right priorities in a COVID-19 world
Environment, Social and Governance Setting the right priorities in a COVID-19 world ESG priorities confirmed Sustainability progress in 2020 Corporate governance update “Better medicine for more people” Rating improvements across the board, New Management Board remuneration Highlights: CDP Climate f
Slide 8: Refreshed materiality analysis in 2020
Environment, Social and Governance Refreshed materiality analysis in 2020 - core priorities confirmed, new topics added Well-being of the Digital Transformation Employees patient & Innovation Access to health care Digitilization & Innovation Working conditions, recruitment and medicine & emplo
Slide 9: ESG Rating overview
ESG Rating overview Continuous improvement through reporting and engagement CDP Climate: B 50/100 Current Score Prime C BBB 17.8 Low Risk CDP Water: C DJSI Europe Sector Average CDP Climate: C C- BBB - A 28 / 100 Medium Risk CDP Climate: C Previous Score Prime C BB 39/100 19.6 Low Risk CDP Water: C
Slide 10: Global sales base in growing, non-cyclical markets
Fresenius Group: Global sales base in growing, non-cyclical markets 2020 Sales by Region Sales in € bn 6% 35,409 36,277 CAGR 33,886 33,530 Latin America Africa 29,471 4% 1% Asia-Pacific 10% €36.3 bn Europe 4,612 44% 4,830 4,688 4,302 4,561 North America 41% 2016 2017 2018 2019 2020 EBIT Before spe
Slide 11: Strong track record of organic sales growth
Strong track record of organic sales growth 5% 7% 7% 7% 7% CAGR 5% 5% 4% 4% 4% 6% 6% 3% 5% ´16 ´17 ´18 ´19 ´20 ´16 ´17 ´18 ´19 ´20 4% 3% 16% 16% 4% 5% 4% 4% 3% 6% 5% ´16 ´17 ´18 ´19 ´20 ´16 ´17 ´18 ´19 ´20 ´16 ´17 ´18 ´19 ´20 -8% Shaded areas show estimated COVID-19 effects Credit Presentation June
Slide 12: Strong and balanced health care portfolio
Strong and balanced health care portfolio Ownership: ~32% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services Health Care Services for Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc
Slide 13: Fresenius Medical Care: Global dialysis market leader
Fresenius Medical Care: Global dialysis market leader • The world’s leading provider of dialysis Sales by region Market dynamics products and services treating ~344,000 patients1 in ~4,100 clinics1 Asia-Pacific North America Increase in worldwide demand • Provide highest standard of product and Lati
Slide 14: Fresenius Kabi: A leading global hospital supplier
Fresenius Kabi: A leading global hospital supplier • Comprehensive product portfolio for Sales by region Market dynamics critically and chronically ill patients • Strong Emerging Markets presence Growing healthcare spending • Leading market positions Emerging Markets in Emerging Markets 31% +6.3% p.
Slide 15: Fresenius Helios: Europe's largest private hospital operator
Fresenius Helios: Europe’s largest private hospital operator • Market leader in size and quality with Sales by region Market dynamics excellent growth prospects • ~5%1 share in German acute care Hospital market in Germany hospital ~12%1 share in Spanish private hospital market ~ € 109 bn • Quality i
Slide 16: Fresenius Vamed: Leading global hospital projects and services specialist
Fresenius Vamed: Leading global hospital projects and services specialist • Manages hospital construction/expansion Sales by region Market dynamics projects and provides services for health care facilities worldwide Emerging Markets Telemedicine market in Europe • Offers project development, plannin
Slide 17: Strategic update
Agenda 01 03 04 Company overview 02 Financial review Credit highlights FY/20 & Strategic Outlook FY/21 update Credit Presentation June 2021 © Fresenius SE & Co. KGaA 17
Slide 18: The Fresenius strategy
The Fresenius strategy Improve profitability Drive Quality Internation- alization Hospital Dialysis supplies & products & Innovation services services Employees Better Hospital projects & medicine and Hospital operations services health care services for ever more people Forward thinking healthcare
Slide 19: Growth areas
Growth areas Worldwide growing Growing Markets with Marketing of existing Attractive markets dialysis market High Entry Barriers value chain Strengthening Standardizing Attractive Market and extension medical procedures Product Pipeline consolidation of value chain Home dialysis Entry into attractiv
Slide 20: Strategic roadmap
Strategic roadmap 3 Operational excellence Growth drivers Accelerate Capital allocation Significant cost savings Strategic evaluation 2 Launch Idacio in US Growth areas: Biosimilars, Fertility, Grow Digital services, Home-hemodialysis First meaningful cost savings Balance sheet flexibility Value cre
Slide 21: Medium-term growth targets 2020 – 2023
Fresenius Group: Medium-term growth targets 2020 – 2023 (CAGRs) 4 – 7% Organic sales growth (plus ~1% small to mid-size confirmed acquisitions) 5 – 9% Organic net income1 growth (plus ~1% small to mid-size acquisitions) confirmed 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA B
Slide 22: Financial review Q1/21 & Outlook FY/21
Agenda 01 02 04 Company overview Strategic update 03 Credit highlights Financial review Q1/21 & Outlook FY/21 Credit Presentation June 2021 © Fresenius SE & Co. KGaA 22
Slide 23: Q1/21 Profit and loss statement
Q1/21 Profit and loss statement Sales EBIT +3% -6% Net Income Q1/21: €8,984 m Q1/21: €1,006 m -2% Income Tax Rate Net Interest Q1/21: €435 m 22.8% -€137 m Q1/20: 22.6% Q1/20: -€174 m All growth rates in constant currency (cc) Before special items Net income attributable to shareholders of Fresenius
Slide 24: Key messages
Key messages Good start to the year; Ongoing decisive efforts to Cost & efficiency program: Guidance FY/21 confirmed robust growth rates despite combat COVID-19 Savings of at least €100 m tough prior year comp p.a. after tax and minorities in 2023 Delivers solid first quarter in Ongoing headwinds in
Slide 25: Update cost & efficiency program
Fresenius Group: Update cost & efficiency program – preliminary expectation for business segment focus categories 1 Category Corporate Procurement, direct costs and cost measures Structural & Organizational measures Portfolio review & Real Estate Contributions to cost savings / preliminary ¼: Medium
Slide 26: Q1/21 Business segment growth
Q1/21 Business segment growth Organic sales growth EBIT growth (cc) +1% -8% +3% +2% +4% -1% -4% -129% +2% -6% All figures before special items For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center. Credit Presen
Slide 27: Q1/21 Cash flow
Q1/21 Cash flow Operating CF Capex (net) Free Cash Flow1 €m Q1/2021 LTM Margin Q1/2021 LTM Margin Q1/2021 LTM Margin 208 21.9% -179 -5.3% 29 16.6% 278 17.9% -132 -9.3% 146 8.6% 215 12.2% -77 -5.3% 138 6.9% -44 2.6% -22 -3.7% -66 -1.1% Corporate/Other -5 n.a. -1 n.a. -6 n.a. 444 13.9% -232 -6.9% 212
Slide 28: FY/21 Financial outlook by business segment
FY/21 Financial outlook by business segment €m (except otherwise stated) FY/20 Base Q1/21 FY/21e FY/21e Low-to-mid single- Sales growth (org) 6,976 3% confirmed digit % Stable to low single- EBIT growth (cc) 1,095 2% confirmed digit % Low-to-mid single- Sales growth (org) 9,818 4% confirmed digit %
Slide 29: FY/21 Financial guidance
FY/21 Financial guidance €m (except otherwise stated) FY/20 Base Q1/21 FY/21e FY/21e Sales growth (cc) 36,277 3% Low-to-mid confirmed single-digit % Net income growth (cc) 1,796 -2% At least confirmed broadly stable Before special items and including estimated COVID-19 effects Net income attributabl
Slide 30: Credit highlights
Agenda 01 02 03 Company overview Strategic update Financial review 04 Q1/21 & Outlook FY/21 Credit highlights Credit Presentation June 2021 © Fresenius SE & Co. KGaA 30
Slide 31: Strong financial position
Strong financial position Well-diversified sales and earnings base Consistent cash generation Well-balanced maturity profile High financial flexibility ensured by broad mix of Solid IG Rating Commitment financing instruments to long-standing net debt/EBITDA Excellent reputation target of 3.0-3.5x in
Slide 32: Strong cash generation
Strong cash generation CFFO margin FCF margin (before acquisitions & dividends) % % 18.1 15 11.5 10 14 12,6 9 13 12,0 12,2 7.6 11,4 11,6 12,0 8 12 11,2 6.7 6.7 6.6 10,9 6.2 11 10,3 7 5.6 10 6 5.2 5.0 5.2 9 5 8 4 1 1 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2011 2012 2013 2014 2015 2016 2017
Slide 33: Proven track record of deleveraging
Proven track record of deleveraging Net Debt/EBITDA1 Standard & Hospitals from Poor’s BBB 4,0 4.0 Outlook stable 3.6x 3.6x 4 3.5x 3.5x 3,5 3.5 3.4x Moody’s 3.2x 3.2x 3.1x 3 3.0x 3.0x 3.0x Baa3 3,0 3.0 2.8x Outlook stable 2.7x 2.7x 2.7x 2.6x 2.6x 2.6x 2.7x 2,5 2.5x Fitch 2.5 2.3x 2.2x 2.3x BBB- 2,0 2
Slide 34: Broad mix of financing instruments
Fresenius Group excl. FMC: Broad mix of financing instruments1,2,3 Well Positioned to Meet Financing Needs Equity-neutral convertible bonds 4% Bonds 60% • Optimize funding costs and ensure Other financial liabilities 8% financial flexibility • Diversify investor base Commercial Paper 2% • Strong liq
Slide 35: Major long-term debt maturities
1,2,3 Fresenius Group excl. FMC: Major long-term debt maturities €m 2.500 Maturity 5.0 years on average 2.000 500 207 1.500 421 1.000 393 1.450 238 1.250 1.150 84 500 425 1.000 700 500 500 500 500 500 500 244 0 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Bonds Schuldschein Loans
Slide 36: Solid Balance Sheet structure
Fresenius Group: Solid Balance Sheet structure B/S total (€bn) 46.7 53.1 56.7 67.0 66.6 • Healthy Equity and Liability Split 41% 40% 39% • Strong equity ratio of >40% on average 45% 44% • Equity ratio kept in narrow range despite rapid growth of Fresenius Group 36% 33% 41% 39% 32% 23% 23% 23% 19% 22
Slide 37: Fresenius SE: Solid Investment Grade rating
Fresenius SE: Solid Investment Grade rating Rating history Rating Agencies’ key statements “The stable outlook reflects our expectation that, despite some near-term challenges from the pandemic, the group’s diversified and resilient business model should support strong recovery prospects.” S&P July
Slide 38: Strong access to capital markets
Fresenius Group: Strong access to capital markets Major financing instruments 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Bonds €250m €800m €750m €500m €1.2bn $300m €2.6bn €500m €1.0bn €750m €1.5bn1 $1.05bn $1.5bn $1.2bn $500m €750m $1.5bn2 €1.75bn €1.25bn $1.0bn €1.0bn Syndicated $1
Slide 39: Debt and cash flow structure
Fresenius Group: Debt and cash flow structure Fresenius Medical Fresenius SE Care Financing Financing • Separate financing of Fresenius SE and Fresenius Medical Care Group Net Debt: ~€24.6 bn1 • No joint financing facilities or mutual guarantees • Fresenius Kabi, Fresenius Helios and FSE Net Debt2:
Slide 40: Financial calendar / contact
Financial calendar / contact Financial calendar Contact 30 July 2021 Results Q2/21 Investor Relations & Sustainability 02 November 2021 Results Q3/21 Fresenius SE & Co. KGaA phone: +49 6172 608-2485 Please note that these dates could be subject to change. e-mail: ir-fre@fresenius.com For further inf
Fresenius SE & Co. KGaA — Debt Investor Presentation (June 2021) on 6ix